Onyx Pharmaceuticals, Inc. Message Board
- Reply to
Article : Market is Large Enough for a Bare Minimum $1 Billion. AMRN VERY OVERSOLD. // LINK
by wesleydoctor •Mar 31, 2013 6:35 PMlkj-if see this email me.
- Reply to
If U Look at the 3 Month chart- last time this went this low- shot right back up to highs.
by ccharles792 •Mar 28, 2013 11:44 AMthanks.
- Reply to
Shorts & Their " The Sky is Falling" Bad Acting Jobs On This Board are Hilarious.......read.
by fromnyjohn •Mar 29, 2013 1:24 PMshorts won't be happy Mon when bounce comes an we go over $8 again.
- Reply to
Very Worried About Mon After That Seeking Article, Will be Damaging I'm Afriad.
by kurtmanning456 •Mar 29, 2013 1:32 PMwe all should be worried
- Reply to
Last Time An Article Like This Came Out- Went Down $3.00, I'm Also Worried : (
by going1green •Mar 30, 2013 1:19 AMbig dump coming I predict, bad article out.
- Reply to
Brian Nicholas Seeking Alpha 3/30 5 Stocks To Watch For Gains This Week (AMRN)
by stevealexander139 •Mar 30, 2013 11:01 PMno brainer going up.
- Reply to
Seeking Alpha " AMRN VERY OVERSOLD. Will POP Off Bottom Range Next Week" (( LINK ))
by stevealexander139 •Mar 30, 2013 10:59 PMgreat article.. drug only been sold for 2 months..will be big winner.
-
Seeking Alpha (Saturday )
5 Stocks To Watch For Gains This Week
Mar 30 2013 By: Brian Nichols
The drug, as currently approved, has market potential around $1 billion, judging by the success of Lovaza. Due to the success of its trial ANCHOR and the market potential of elevated triglyceride levels, which is eight times larger, I am not sure how Amarin is not a buy right now for the long term, in addition to short term. Assuming its indication is expanded, as I believe it will, I think the market is large enough for a bare minimum $1 billion in sales. Therefore, with the stock being very oversold, I wouldn't be surprised to see pop off its current bottom range next week. In addition, if $1 billion in sales is achieved (minimum) then the typical 3-4 times sales should also be expected, therefore presenting great upside. -
Seeking Alpha By: Briam Wilson 3/26/13
Pimavanserin is an inverse agonist of the serotonin receptor 5-HT2A. Molecules working through the same mechanism of action have had limited success so far, which is why pimavanserin in a particularly attractive molecule right now that may pique the interest of other pharmaceutical companies interested in expansion of their psychotic drug pipelines.
This, combined with Acadia's (still) low market capitalization of ~$660 million (at the time of writing) makes
Acadia a prime acquisition target for big pharmaceutical companies, particular those that are struggling with their top-line growth. - Reply to
Under $10 Sounds Pretty Cheap for Only Parkinson Pychosis Drug & Aquistion Target.
by spencer_doc •Mar 26, 2013 11:11 AMadded
- Reply to
Thanks for the Cheap Shares : ) Will be a Major Biotech Player.
by iminjim •Mar 26, 2013 11:49 AMim in
- Reply to
Cramer " ACAD IS THE REAL DEAL. HOLD ONTO IT, IT'S A FANTASTIC SPEC" seeking alpha link.
by larrystone13 •Mar 24, 2013 2:54 PMbig run up coming
-
Seeking Alpha By: Brian Nichlos 3/25/13
Last week there were several big-time performances in the small cap biotechnology space. While I view each stock differently, I do acknowledge that at this point, all have great upside potential. In my opinion, ACADIA is the safest, -
-
- Reply to
Seeking Article ,Scott Matusow Big Pharma's WANT Acadia. (( LINK ))
by ytodd36 •Mar 21, 2013 3:45 PMnice!
- Reply to
Cramer " ACAD IS THE REAL DEAL. HOLD ONTO IT, IT'S A FANTASTIC SPEC" seeking alpha link.
by larrystone13 •Mar 24, 2013 2:54 PMthis baby going up $9.50 to $10 Mon.
- Reply to
I Don't Base My Trading On A Fund Manager Who Is Short. Bought 7K
by theman111knows •Mar 22, 2013 9:57 AMLOL,, me neither